IntegraGen Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
IntegraGen has been growing earnings at an average annual rate of 48.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 13.4% per year.
Anahtar bilgiler
48.1%
Kazanç büyüme oranı
45.9%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 30.8% |
Gelir büyüme oranı | 13.4% |
Özkaynak getirisi | -8.5% |
Net Marj | -1.4% |
Son Kazanç Güncellemesi | 31 Dec 2023 |
Gelir ve Gider Dağılımı
IntegraGen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Dec 23 | 13 | 0 | 5 | 0 |
30 Sep 23 | 13 | 0 | 5 | 0 |
30 Jun 23 | 13 | 0 | 5 | 0 |
31 Mar 23 | 13 | 0 | 5 | 0 |
31 Dec 22 | 13 | 0 | 5 | 0 |
30 Sep 22 | 13 | 0 | 3 | 0 |
30 Jun 22 | 13 | 0 | 0 | 0 |
31 Mar 22 | 12 | 0 | 0 | 0 |
31 Dec 21 | 11 | 0 | 0 | 0 |
30 Sep 21 | 10 | 0 | 3 | 0 |
30 Jun 21 | 9 | -1 | 6 | 0 |
31 Mar 21 | 9 | -1 | 6 | 0 |
31 Dec 20 | 9 | 0 | 6 | 0 |
30 Sep 20 | 9 | 0 | 6 | 0 |
30 Jun 20 | 9 | 0 | 6 | 0 |
31 Mar 20 | 9 | 0 | 6 | 0 |
31 Dec 19 | 8 | 0 | 6 | 0 |
30 Sep 19 | 8 | -1 | 4 | 0 |
30 Jun 19 | 7 | -1 | 3 | 0 |
31 Mar 19 | 7 | -1 | 3 | 0 |
31 Dec 18 | 7 | -1 | 3 | 0 |
30 Sep 18 | 7 | -1 | 3 | 0 |
30 Jun 18 | 7 | -1 | 3 | 0 |
31 Mar 18 | 7 | -1 | 3 | 0 |
31 Dec 17 | 7 | -1 | 3 | 0 |
30 Sep 17 | 6 | -1 | 4 | 0 |
30 Jun 17 | 7 | -1 | 3 | 0 |
31 Mar 17 | 6 | -1 | 3 | 0 |
31 Dec 16 | 6 | -2 | 3 | 0 |
30 Sep 16 | 6 | -2 | 3 | 0 |
30 Jun 16 | 6 | -2 | 3 | 0 |
31 Mar 16 | 6 | -2 | 3 | 0 |
31 Dec 15 | 6 | -2 | 3 | 0 |
30 Sep 15 | 6 | -1 | 3 | 0 |
30 Jun 15 | 6 | -1 | 3 | 0 |
31 Mar 15 | 6 | -1 | 3 | 0 |
31 Dec 14 | 6 | -1 | 3 | 0 |
30 Sep 14 | 6 | -1 | 3 | 0 |
30 Jun 14 | 5 | -2 | 3 | 0 |
31 Mar 14 | 5 | -2 | 3 | 0 |
31 Dec 13 | 5 | -3 | 3 | 0 |
Kaliteli Kazançlar: ALINT is currently unprofitable.
Büyüyen Kar Marjı: ALINT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ALINT is unprofitable, but has reduced losses over the past 5 years at a rate of 48.1% per year.
Büyüme Hızlandırma: Unable to compare ALINT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: ALINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Özkaynak Getirisi
Yüksek ROE: ALINT has a negative Return on Equity (-8.52%), as it is currently unprofitable.